Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
SummaryQuotesChartsNewsRatingsCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

M&A market remains strong despite decline in activity

12/07/2021 | 10:26am EST

New figures published today by the Office of National Statistics have revealed a fall in deal values across inward and domestic deals in Q3, but a sharp increase in the value of outward M&A deals.

Outward M&A values climbed significantly to 32.8bn in Q3 from 8.2bn in Q2, boosted by an estimated £10bn ($13.3bn*) acquisition of Alexion Pharmaceuticals INC by AstraZeneca. Inward M&A values fell to 10.7bn in Q3 from 28.7bn in Q2; and domestic deal values were also down to 3.1bn in Q3 from 4.4bn in Q2.

In total, there were 136 completed deals in September 2021, down from 164 in June 2021 and well below the elevated levels of activity seen in Q1, with 292 deals completed in March 2021.

Kirsty Sandwell, partner and head of transactions at RSM said: 'The level of M&A deal activity has been in a hot bubble over the past year, but is now gradually cooling down, moving from frantic to strong.

'Globalisation has meant that buyers are using M&A for cross-border growth rather than domestic growth. In particular, the US private equity market is investing billions of dollars into the US mid-market, meaning it now has increased confidence to invest into the UK and Europe in much greater numbers than in the past. Companies looking to exit will want to ensure they are as attractive as possible to private equity funds and overseas businesses.

'The effects of Brexit have been largely masked by Covid, but some businesses are beginning to look at the prospect of offshoring their operations to bypass the shortage of labour in the UK.

'As we emerge from the pandemic, the strong M&A activity looks set to continue until normal levels of business distress return, as many zombie businesses have been propped up by Government support, which has now ended. The high amount of uninvested capital means the market will hopefully have a softer landing when the bubble eventually bursts, which may happen around mid-next year.' /Ends.

*Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Acquisition of Alexion completed

Media enquiries

RSM press office

Mel Matthews, PR Manager, 07436 268533

Kelly Vuong, PR executive, 0203 201 8042

Notes to editor

RSM: is a leading audit, tax and consulting firm to the middle market with 3,650 partners and staff operating from 32 locations throughout the UK. For the year ending 31 March 2020, RSM generated revenues of £356m. RSM UK is a member firm of RSM International - the sixth largest network of audit, tax and consulting firms globally. The network spans more than 120 countries, 820 offices and 48,000 people, with a fee income of $6.3bn.

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ALEXION PHARMACEUTICALS, INC. 1.70% 182.5 End-of-day quote.0.00%
ASTRAZENECA PLC -1.11% 8744 Delayed Quote.0.85%
All news about ALEXION PHARMACEUTICALS, INC.
01/10AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurim..
CI
2021M&A market remains strong despite decline in activity
AQ
2021LIFE SCIENCES : Vavilov And The New Regulatory Environment
AQ
2021ALEXION PHARMACEUTICALS : Canada Seeks Leave To Appeal To The Supreme Court In PMPRB Exces..
AQ
2021Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in ..
CI
2021OCULAR THERAPEUTIX : Announces appointment of karen-leigh edwards as senior vice president..
AQ
2021AstraZeneca's Alexion to Advance and Accelerate Ongoing Phase III Clinical Development ..
CI
2021Alexion Pharmaceuticals, Inc. agreed to acquire remaining majority stake in Caelum Bios..
CI
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2020 6 070 M - -
Net income 2020 603 M - -
Net cash 2020 68,0 M - -
P/E ratio 2020 57,4x
Yield 2020 -
Capitalization 40 336 M 40 336 M -
EV / Sales 2019 4,81x
EV / Sales 2020 5,62x
Nbr of Employees 3 837
Free-Float -
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Income Statement Evolution
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors